Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 643,720
  • Shares Outstanding, K 47,090
  • Annual Sales, $ 1,540 K
  • Annual Income, $ -135,750 K
  • 36-Month Beta 1.07
  • Price/Sales 419.34
  • Price/Cash Flow 0.00
  • Price/Book 17.34

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.42 +2.98%
on 07/20/17
16.54 -16.44%
on 06/22/17
-2.02 (-12.75%)
since 06/21/17
3-Month
9.16 +50.87%
on 04/24/17
16.54 -16.44%
on 06/22/17
+4.72 (+51.87%)
since 04/21/17
52-Week
7.16 +93.02%
on 11/03/16
16.54 -16.44%
on 06/22/17
+5.22 (+60.70%)
since 07/21/16

Most Recent Stories

More News
Shares of AKBA Up 39.6% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on December 20th, 2016 at $10.03. In approximately 7 months, Akebia Therapeut has returned 39.58% as of today's recent price of $14.00....

AKBA : 13.82 (+1.10%)
Akebia Therapeut Has Returned 44.2% Since SmarTrend Recommendation (AKBA)

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on December 20th, 2016 at $10.03. In approximately 7 months, Akebia Therapeut has returned 44.17% as of today's recent price of $14.46....

AKBA : 13.82 (+1.10%)
Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

MS : 46.59 (+0.17%)
AKBA : 13.82 (+1.10%)
Akebia Announces Pricing of Public Offering of Common Stock

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

MS : 46.59 (+0.17%)
AKBA : 13.82 (+1.10%)
Uptrend Call Working As Akebia Therapeut Stock Rises 61.7% (AKBA)

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on December 20th, 2016 at $10.03. In approximately 6 months, Akebia Therapeut has returned 61.71% as of today's recent price of $16.22....

AKBA : 13.82 (+1.10%)
Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor...

AKBA : 13.82 (+1.10%)
Technical Insights on Biotech Stocks -- Soligenix, Sorrento Therapeutics, Alcobra, and Akebia Therapeutics

On Thursday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.39%; the Dow Jones Industrial Average edged 0.04% higher; and the S&P 500 was up 0.03%....

SRNE : 2.05 (unch)
ADHD : 1.13 (-0.88%)
AKBA : 13.82 (+1.10%)
SNGX : 2.68 (-6.62%)
SNGXD : 4.1500 (-5.68%)
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

Quite a few deals were announced this week including by companies like Biogen (BIIB).

SGMO : 9.50 (-0.52%)
AKBA : 13.82 (+1.10%)
VRTX : 163.17 (+2.41%)
IONS : 56.39 (+0.95%)
REGN : 515.92 (-1.00%)
ALXN : 131.79 (+1.53%)
BIIB : 282.92 (+0.53%)
Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

Vifor Pharma Ltd. / Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval . Processed and transmitted by Nasdaq Corporate...

AKBA : 13.82 (+1.10%)
Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

--- Additional Funds Support Vadadustat Global Development Program to Data a^'

AKBA : 13.82 (+1.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Support & Resistance

2nd Resistance Point 14.27
1st Resistance Point 14.04
Last Price 13.82
1st Support Level 13.62
2nd Support Level 13.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.